TY - JOUR
T1 - Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction
AU - Ather, Sameer
AU - Chan, Wenyaw
AU - Bozkurt, Biykem
AU - Aguilar, David
AU - Ramasubbu, Kumudha
AU - Zachariah, Amit A.
AU - Wehrens, Xander H.T.
AU - Deswal, Anita
N1 - Funding Information:
This study was supported in part by VA Health Services Research & Development Service grant IIR 02-082-1 to Dr. Deswal. Dr. Ather is supported by an American Heart Association predoctoral fellowship (2010–2012) and an Alkek Foundation fellowship (2009–2012). Dr. Bozhurt has received a research grant from Forest Pharmaceuticals . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2012/3/13
Y1 - 2012/3/13
N2 - Objectives: The aim of this study was to evaluate the prevalence and prognostic impacts of noncardiac comorbidities in patients with heart failure (HF) with preserved ejection fraction (HFpEF) compared with those with HF with reduced ejection fraction (HFrEF). Background: There is a paucity of information on the comparative prognostic significance of comorbidities between patients with HFpEF and those with HFrEF. Methods: In a national ambulatory cohort of veterans with HF, the comorbidity burden of 15 noncardiac comorbidities and the impacts of these comorbidities on hospitalization and mortality were compared between patients with HFpEF and those with HFrEF. Results: The cohort consisted of 2,843 patients with HFpEF and 6,599 with HFrEF with 2-year follow-up. Compared with patients with HFrEF, those with HFpEF were older and had higher prevalence of chronic obstructive pulmonary disease, diabetes, hypertension, psychiatric disorders, anemia, obesity, peptic ulcer disease, and cancer but a lower prevalence of chronic kidney disease. Patients with HFpEF had lower HF hospitalization, higher non-HF hospitalization, and similar overall hospitalization compared with those with HFrEF (p < 0.001, p < 0.001, and p = 0.19, respectively). An Increasing number of noncardiac comorbidities was associated with a higher risk for all-cause admissions (p < 0.001). Comorbidities had similar impacts on mortality in patients with HFpEF compared with those with HFrEF, except for chronic obstructive pulmonary disease, which was associated with a higher hazard (1.62 [95% confidence interval: 1.36 to 1.92] vs. 1.23 [95% confidence interval: 1.11 to 1.37], respectively, p = 0.01 for interaction) in patients with HFpEF. Conclusions: There is a higher noncardiac comorbidity burden associated with higher non-HF hospitalizations in patients with HFpEF compared with those with HFrEF. However, individually, most comorbidities have similar impacts on mortality in both groups. Aggressive management of comorbidities may have an overall greater prognostic impact in HFpEF compared to HFrEF.
AB - Objectives: The aim of this study was to evaluate the prevalence and prognostic impacts of noncardiac comorbidities in patients with heart failure (HF) with preserved ejection fraction (HFpEF) compared with those with HF with reduced ejection fraction (HFrEF). Background: There is a paucity of information on the comparative prognostic significance of comorbidities between patients with HFpEF and those with HFrEF. Methods: In a national ambulatory cohort of veterans with HF, the comorbidity burden of 15 noncardiac comorbidities and the impacts of these comorbidities on hospitalization and mortality were compared between patients with HFpEF and those with HFrEF. Results: The cohort consisted of 2,843 patients with HFpEF and 6,599 with HFrEF with 2-year follow-up. Compared with patients with HFrEF, those with HFpEF were older and had higher prevalence of chronic obstructive pulmonary disease, diabetes, hypertension, psychiatric disorders, anemia, obesity, peptic ulcer disease, and cancer but a lower prevalence of chronic kidney disease. Patients with HFpEF had lower HF hospitalization, higher non-HF hospitalization, and similar overall hospitalization compared with those with HFrEF (p < 0.001, p < 0.001, and p = 0.19, respectively). An Increasing number of noncardiac comorbidities was associated with a higher risk for all-cause admissions (p < 0.001). Comorbidities had similar impacts on mortality in patients with HFpEF compared with those with HFrEF, except for chronic obstructive pulmonary disease, which was associated with a higher hazard (1.62 [95% confidence interval: 1.36 to 1.92] vs. 1.23 [95% confidence interval: 1.11 to 1.37], respectively, p = 0.01 for interaction) in patients with HFpEF. Conclusions: There is a higher noncardiac comorbidity burden associated with higher non-HF hospitalizations in patients with HFpEF compared with those with HFrEF. However, individually, most comorbidities have similar impacts on mortality in both groups. Aggressive management of comorbidities may have an overall greater prognostic impact in HFpEF compared to HFrEF.
KW - comorbidities
KW - diastolic heart function
KW - heart failure with preserved ejection fraction
KW - heart failure with reduced ejection fraction
KW - prognosis
UR - http://www.scopus.com/inward/record.url?scp=84857857236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857857236&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2011.11.040
DO - 10.1016/j.jacc.2011.11.040
M3 - Article
C2 - 22402071
AN - SCOPUS:84857857236
SN - 0735-1097
VL - 59
SP - 998
EP - 1005
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 11
ER -